创刊十年以来，Journal of Experimental and Clinical Cancer Research已逐步跻身于肿瘤学期刊前列。值此十周年之际，又恰逢2017年度期刊影响力数据公布，我们很高兴通过这次特别的机会对期刊过去十年的发展之路进行回顾。

精选文章

Apoptosis in cancer: from pathogenesis to treatment

Wong, R

DOI: 10.1186/1756-9966-30-87

Health-related quality of life in breast cancer patients: A bibliographic review of the literature from 1974 to 2007

Montazeri, A

DOI: 10.1186/1756-9966-27-32

Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients

Zhang, M. et al.

DOI: 10.1186/1756-9966-27-85

MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression

Song, B. et al.

DOI: 10.1186/1756-9966-29-29

miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc

Chen, Z. et al.

DOI: 10.1186/1756-9966-29-151

访问肿瘤学开放获取页面，了解更多肿瘤学期刊的新闻、内容集锦以及近期活动，请点击：https://www.biomedcentral.com/p/oncology-open-access-research?utm_source=WeChat&utm_medium=Social_media_organic&utm_content=DaiDen-BMC-Journal_of_Experimental_and_Clinical_Cancer_Research-Oncology-China&utm_campaign=AJH_AWA_BSCN_DD_10th_Anniversary_Wechat

期刊介绍：根据《期刊引证报告》，Journal of Experimental and Clinical Cancer Research在肿瘤学期刊中排名前列，同时也是意大利罗马Regina Elena国立癌症研究所的官方期刊。

本期刊发表基础肿瘤学、临床肿瘤学、转化肿瘤学研究等方面的高质量多学科研究，无论对肿瘤科医生还是肿瘤学研究人员而言，都是极富价值的宝贵资源。

作为一本开放获取期刊，Journal of Experimental and Clinical Cancer Research的读者遍布世界各地。此外，期刊审稿迅速，通常在提交后30天内可获得一审结果。

2017 Journal Metrics

6.217—2-year Impact Factor

5.280—5-year Impact Factor

1.350—Source Normalized Impact per Paper (SNIP)

2.000 - SCImago Journal Rank (SJR)

599727 Downloads

向Journal of Experimental and Clinical Cancer Research投稿的理由

根据《期刊引证报告》，Journal of Experimental and Clinical Cancer Research在肿瘤学期刊中名列前茅

快速同行评议——平均初审周期仅30天

开放获取：可免费永久在线获取，以积极促进学术交流

（来源：科学网）